Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia

Rosaria Di Lorenzo1, Alice Brogli21Department of Mental Health, AUSL-MODENA, Presidio Psichiatrico di Diagnosi e Cura 1, NOCSAE, Baggiovara, Modena, Italy; 2School of Specialization in Psychiatry, University of Modena e Reggio Emilia, Modena, ItalyAbstract: Olanzapine long-acting injection (OLAI) is...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rosaria Di Lorenzo, Alice Brogli
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/b7f92fe5a5164c52bd42c81a2c87c99e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b7f92fe5a5164c52bd42c81a2c87c99e
record_format	dspace
spelling	oai:doaj.org-article:b7f92fe5a5164c52bd42c81a2c87c99e2021-12-02T01:46:11ZProfile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia1176-63281178-2021https://doaj.org/article/b7f92fe5a5164c52bd42c81a2c87c99e2010-09-01T00:00:00Zhttp://www.dovepress.com/profile-of-olanzapine-long-acting-injection-for-the-maintenance-treatm-a5179https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Rosaria Di Lorenzo1, Alice Brogli21Department of Mental Health, AUSL-MODENA, Presidio Psichiatrico di Diagnosi e Cura 1, NOCSAE, Baggiovara, Modena, Italy; 2School of Specialization in Psychiatry, University of Modena e Reggio Emilia, Modena, ItalyAbstract: Olanzapine long-acting injection (OLAI) is a crystalline salt composed of olanzapine and pamoic acid, which permits a depot intramuscular formulation of olanzapine. The half-life of olanzapine pamoate is 30 days, and its steady state is reached approximately at 12 weeks. Oral supplementation of olanzapine is not required during OLAI initiation, according to Eli Lilly recommendations, although a study indicated that &ge;60% of D2 receptor occupancy was reached only by the fifth injection cycle. To date, a short-term, placebo-controlled study of 8 weeks in acutely ill patients and a long-term, controlled trial of 24 weeks in stabilized patients have been conducted. In both the studies, efficacy and safety were similar to those of oral olanzapine, with the exception of an acute adverse effect, the so-called inadvertent intravascular injection event, which occurred 1&ndash;3 hours after the injection with an incidence rate of 0.07% per injection. It consisted of symptoms that are similar to those reported in cases of oral olanzapine overdose. The most significant studies published to date, on the use of olanzapine pamoate in schizophrenia, are reviewed in this article. The pharmacodynamic and pharmacokinetic profile and related side effects of OLAI are reported.Keywords: olanzapine pamoate long-acting injection, efficacy, safety Rosaria Di LorenzoAlice BrogliDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2010, Iss Issue 1, Pp 573-581 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Rosaria Di Lorenzo Alice Brogli Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
description	Rosaria Di Lorenzo1, Alice Brogli21Department of Mental Health, AUSL-MODENA, Presidio Psichiatrico di Diagnosi e Cura 1, NOCSAE, Baggiovara, Modena, Italy; 2School of Specialization in Psychiatry, University of Modena e Reggio Emilia, Modena, ItalyAbstract: Olanzapine long-acting injection (OLAI) is a crystalline salt composed of olanzapine and pamoic acid, which permits a depot intramuscular formulation of olanzapine. The half-life of olanzapine pamoate is 30 days, and its steady state is reached approximately at 12 weeks. Oral supplementation of olanzapine is not required during OLAI initiation, according to Eli Lilly recommendations, although a study indicated that &ge;60% of D2 receptor occupancy was reached only by the fifth injection cycle. To date, a short-term, placebo-controlled study of 8 weeks in acutely ill patients and a long-term, controlled trial of 24 weeks in stabilized patients have been conducted. In both the studies, efficacy and safety were similar to those of oral olanzapine, with the exception of an acute adverse effect, the so-called inadvertent intravascular injection event, which occurred 1&ndash;3 hours after the injection with an incidence rate of 0.07% per injection. It consisted of symptoms that are similar to those reported in cases of oral olanzapine overdose. The most significant studies published to date, on the use of olanzapine pamoate in schizophrenia, are reviewed in this article. The pharmacodynamic and pharmacokinetic profile and related side effects of OLAI are reported.Keywords: olanzapine pamoate long-acting injection, efficacy, safety
format	article
author	Rosaria Di Lorenzo Alice Brogli
author_facet	Rosaria Di Lorenzo Alice Brogli
author_sort	Rosaria Di Lorenzo
title	Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
title_short	Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
title_full	Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
title_fullStr	Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
title_full_unstemmed	Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
title_sort	profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/b7f92fe5a5164c52bd42c81a2c87c99e
work_keys_str_mv	AT rosariadilorenzo profileofolanzapinelongactinginjectionforthemaintenancetreatmentofadultpatientswithschizophrenia AT alicebrogli profileofolanzapinelongactinginjectionforthemaintenancetreatmentofadultpatientswithschizophrenia
_version_	1718402919562215424

Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia

Ejemplares similares